Non-bacterial thrombotic endocarditis epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 8: Line 8:
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*Non-bacterial thrombotic endocarditis is a rare autopsy finding<ref name="pmid17535760">{{cite journal |vauthors=Llenas-García J, Guerra-Vales JM, Montes-Moreno S, López-Ríos F, Castelbón-Fernández FJ, Chimeno-García J |title=[Nonbacterial thrombotic endocarditis: clinicopathologic study of a necropsy series] |language=Spanish; Castilian |journal=Rev Esp Cardiol |volume=60 |issue=5 |pages=493–500 |date=May 2007 |pmid=17535760 |doi= |url=}}</ref>.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*It is a rare disease that tends to affect patients with advanced malignancies<ref name="pmid9217593">{{cite journal |vauthors=Edoute Y, Haim N, Rinkevich D, Brenner B, Reisner SA |title=Cardiac valvular vegetations in cancer patients: a prospective echocardiographic study of 200 patients |journal=Am. J. Med. |volume=102 |issue=3 |pages=252–8 |date=March 1997 |pmid=9217593 |doi=10.1016/S0002-9343(96)00457-3 |url=}}</ref><ref name="pmid9043857">{{cite journal |vauthors=Kalangos A, Pretre R, Girardet C, Ricou E, Faidutti B |title=An atypical aortic valve non-bacterial thrombotic endocarditis in the course of multiple myeloma |journal=Eur. Heart J. |volume=18 |issue=2 |pages=351–2 |date=February 1997 |pmid=9043857 |doi=10.1093/oxfordjournals.eurheartj.a015243 |url=}}</ref> and patients with autoimmune disorders<ref name="pmid8608627">{{cite journal |vauthors=Hojnik M, George J, Ziporen L, Shoenfeld Y |title=Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome |journal=Circulation |volume=93 |issue=8 |pages=1579–87 |date=April 1996 |pmid=8608627 |doi=10.1161/01.cir.93.8.1579 |url=}}</ref>.
*Although the exact incidence of NBTE is unknown, it is thought to be approximately 900-600 per 100,000 individuals worldwide<ref name="pmid998478">{{cite journal |vauthors=Deppisch LM, Fayemi AO |title=Non-bacterial thrombotic endocarditis: clinicopathologic correlations |journal=Am. Heart J. |volume=92 |issue=6 |pages=723–9 |date=December 1976 |pmid=998478 |doi=10.1016/s0002-8703(76)80008-7 |url=}}</ref><ref name="pmid1851590">{{cite journal |vauthors=González Quintela A, Candela MJ, Vidal C, Román J, Aramburo P |title=Non-bacterial thrombotic endocarditis in cancer patients |journal=Acta Cardiol |volume=46 |issue=1 |pages=1–9 |date=1991 |pmid=1851590 |doi= |url=}}</ref>.


===Prevalence===
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*The prevalence of NBTE is approximately 9,300 per 100,000 individuals worldwide<ref name="pmid6481938">{{cite journal |vauthors=Kuramoto K, Matsushita S, Yamanouchi H |title=Nonbacterial thrombotic endocarditis as a cause of cerebral and myocardial infarction |journal=Jpn. Circ. J. |volume=48 |issue=9 |pages=1000–6 |date=September 1984 |pmid=6481938 |doi=10.1253/jcj.48.1000 |url=}}</ref>.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
 
===Case-fatality rate/Mortality rate===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].


===Age===
===Age===
*Patients of all age groups may develop [disease name].
*Patients of all age groups may develop NBTE<ref name="pmid3548296">{{cite journal |vauthors=Lopez JA, Ross RS, Fishbein MC, Siegel RJ |title=Nonbacterial thrombotic endocarditis: a review |journal=Am. Heart J. |volume=113 |issue=3 |pages=773–84 |date=March 1987 |pmid=3548296 |doi=10.1016/0002-8703(87)90719-8 |url=}}</ref>.
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
*NBTE commonly affects individuals between the ages of 40-80years of age<ref name="pmid6481938">{{cite journal |vauthors=Kuramoto K, Matsushita S, Yamanouchi H |title=Nonbacterial thrombotic endocarditis as a cause of cerebral and myocardial infarction |journal=Jpn. Circ. J. |volume=48 |issue=9 |pages=1000–6 |date=September 1984 |pmid=6481938 |doi=10.1253/jcj.48.1000 |url=}}</ref><ref name="pmid13124459">{{cite journal |vauthors=ANGRIST A, MARQUISS J |title=The changing morphologic picture of endocarditis since the advent of chemotherapy and antibiotic agents |journal=Am. J. Pathol. |volume=30 |issue=1 |pages=39–63 |date=1954 |pmid=13124459 |pmc=1942455 |doi= |url=}}</ref>.  
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.  
*[Chronic disease name] is usually first diagnosed among [age group].
*[Acute disease name] commonly affects [age group].


===Race===
===Race===
*There is no racial predilection to [disease name].
*There is no racial predilection to NBTE<ref name="pmid3548296">{{cite journal |vauthors=Lopez JA, Ross RS, Fishbein MC, Siegel RJ |title=Nonbacterial thrombotic endocarditis: a review |journal=Am. Heart J. |volume=113 |issue=3 |pages=773–84 |date=March 1987 |pmid=3548296 |doi=10.1016/0002-8703(87)90719-8 |url=}}</ref>.
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
 
===Gender===
===Gender===
*[Disease name] affects men and women equally.
*NBTE affects men and women equally<ref name="pmid6481938">{{cite journal |vauthors=Kuramoto K, Matsushita S, Yamanouchi H |title=Nonbacterial thrombotic endocarditis as a cause of cerebral and myocardial infarction |journal=Jpn. Circ. J. |volume=48 |issue=9 |pages=1000–6 |date=September 1984 |pmid=6481938 |doi=10.1253/jcj.48.1000 |url=}}</ref><ref name="pmid3548296">{{cite journal |vauthors=Lopez JA, Ross RS, Fishbein MC, Siegel RJ |title=Nonbacterial thrombotic endocarditis: a review |journal=Am. Heart J. |volume=113 |issue=3 |pages=773–84 |date=March 1987 |pmid=3548296 |doi=10.1016/0002-8703(87)90719-8 |url=}}</ref>.
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
 
===Region===
*The majority of [disease name] cases are reported in [geographical region].
 
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].


===Developed Countries===


===Developing Countries===
<br />
<br />
==References==
==References==

Revision as of 20:39, 6 August 2020

non-bacterial thrombotic endocarditis

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating non-bacterial thrombotic endocarditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Non-bacterial thrombotic endocarditis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non-bacterial thrombotic endocarditis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-bacterial thrombotic endocarditis epidemiology and demographics

CDC on Non-bacterial thrombotic endocarditis epidemiology and demographics

Non-bacterial thrombotic endocarditis epidemiology and demographics in the news

Blogs on Non-bacterial thrombotic endocarditis epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Non-bacterial thrombotic endocarditis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aisha Adigun, B.Sc., M.D.[2]

Overview

Epidemiology and Demographics

Incidence

  • Non-bacterial thrombotic endocarditis is a rare autopsy finding[1].
  • It is a rare disease that tends to affect patients with advanced malignancies[2][3] and patients with autoimmune disorders[4].
  • Although the exact incidence of NBTE is unknown, it is thought to be approximately 900-600 per 100,000 individuals worldwide[5][6].

Prevalence

  • The prevalence of NBTE is approximately 9,300 per 100,000 individuals worldwide[7].

Age

  • Patients of all age groups may develop NBTE[8].
  • NBTE commonly affects individuals between the ages of 40-80years of age[7][9].

Race

  • There is no racial predilection to NBTE[8].

Gender

  • NBTE affects men and women equally[7][8].



References

  1. ↑ Llenas-García J, Guerra-Vales JM, Montes-Moreno S, López-Ríos F, Castelbón-Fernández FJ, Chimeno-García J (May 2007). "[Nonbacterial thrombotic endocarditis: clinicopathologic study of a necropsy series]". Rev Esp Cardiol (in Spanish; Castilian). 60 (5): 493–500. PMID 17535760.
  2. ↑ Edoute Y, Haim N, Rinkevich D, Brenner B, Reisner SA (March 1997). "Cardiac valvular vegetations in cancer patients: a prospective echocardiographic study of 200 patients". Am. J. Med. 102 (3): 252–8. doi:10.1016/S0002-9343(96)00457-3. PMID 9217593.
  3. ↑ Kalangos A, Pretre R, Girardet C, Ricou E, Faidutti B (February 1997). "An atypical aortic valve non-bacterial thrombotic endocarditis in the course of multiple myeloma". Eur. Heart J. 18 (2): 351–2. doi:10.1093/oxfordjournals.eurheartj.a015243. PMID 9043857.
  4. ↑ Hojnik M, George J, Ziporen L, Shoenfeld Y (April 1996). "Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome". Circulation. 93 (8): 1579–87. doi:10.1161/01.cir.93.8.1579. PMID 8608627.
  5. ↑ Deppisch LM, Fayemi AO (December 1976). "Non-bacterial thrombotic endocarditis: clinicopathologic correlations". Am. Heart J. 92 (6): 723–9. doi:10.1016/s0002-8703(76)80008-7. PMID 998478.
  6. ↑ González Quintela A, Candela MJ, Vidal C, Román J, Aramburo P (1991). "Non-bacterial thrombotic endocarditis in cancer patients". Acta Cardiol. 46 (1): 1–9. PMID 1851590.
  7. ↑ 7.0 7.1 7.2 Kuramoto K, Matsushita S, Yamanouchi H (September 1984). "Nonbacterial thrombotic endocarditis as a cause of cerebral and myocardial infarction". Jpn. Circ. J. 48 (9): 1000–6. doi:10.1253/jcj.48.1000. PMID 6481938.
  8. ↑ 8.0 8.1 8.2 Lopez JA, Ross RS, Fishbein MC, Siegel RJ (March 1987). "Nonbacterial thrombotic endocarditis: a review". Am. Heart J. 113 (3): 773–84. doi:10.1016/0002-8703(87)90719-8. PMID 3548296.
  9. ↑ ANGRIST A, MARQUISS J (1954). "The changing morphologic picture of endocarditis since the advent of chemotherapy and antibiotic agents". Am. J. Pathol. 30 (1): 39–63. PMC 1942455. PMID 13124459.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Non-bacterial_thrombotic_endocarditis_epidemiology_and_demographics&oldid=1648187"